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Abstract 
Background: Menstrual cycle function may continue to be altered after 
discontinuation of oral contraceptives (OC). Few studies have been published on the 
effects of recent OC use on menstrual cycle parameters; none have examined 
characteristics of the menstrual flow or the quality of cervical mucus. The purpose of this 
retrospective matched cohort study is to assess biomarkers of the menstrual cycle after 
discontinuation of OCs. 
Methods: Among a sample of women who daily recorded observations of 
menstrual cycle biomarkers, 70 women who had recently discontinued OCs were 
randomly matched by age and parity with 70 women who had not used OCs for at least 
1 year. Outcomes investigated included overall cycle length, length of the luteal phase, 
estimated day of ovulation, duration of menstrual flow, menstrual intensity, and mucus 
score. Differences between recent OC users and controls were assessed using random 
effects modeling. 
Results: Recent OC users had statistically significantly lower scores for mucus 
quality for cycles 1 and 2. Additionally, OC users had a later estimated day of ovulation 
that was statistically significant in cycle 2 and a decreased intensity of menstrual flow 
that was significant in the first four cycles (difference = −0.48 days). In random effects 
modeling, all these parameters were significantly different for the first six cycles 
combined. 
Conclusions: Menstrual cycle biomarkers are altered for at least two cycles after 
discontinuation of OCs, and this may help explain the temporary decrease in fecundity 
associated with recent OC use. 
 
  
Introduction 
Oral contraceptives (OC) are the most commonly used reversible method of 
contraception among women between the ages of 15 and 44 in the United States.1 Many of 
these women will eventually discontinue use of OCs in order to achieve a pregnancy. In addition, 
some will use fertility awareness methods to enhance their chances to conceive.2 Accurate 
knowledge of the parameters of the menstrual cycle is important for couples trying to achieve 
pregnancy as well as for couples using natural methods to avoid pregnancy. Therefore, it is of 
interest to know if the menstrual cycle may continue to be altered for some time after 
discontinuation of OCs. 
Few studies have been published on the effects of recent use of OCs onmenstrual cycle 
parameters.3–5 One study compared 175 women discontinuing OCs with 284 similar women 
who never used OCs, where both groups of women charted basal body temperatures (BBT) and 
cervical mucus.5 In that study, the recent OC users had significantly longer cycles than the 
control women. The researchers concluded that although cycle disturbances after 
discontinuation of OCs were reversible, the time required for cycles to normalize was ≥9 months. 
Furthermore, only 57.9% of the women in the study had an ovulatory cycle with the luteal phase 
judged sufficient to achieve pregnancy in their first cycle after OC discontinuation (based on 
thermal shift). They theorized that the delayed normalization of the parameters of the menstrual 
cycle was due to the time necessary for the hypothalamic-pituitary-ovarian axis to normalize 
after being influenced by the exogenous hormones from the OCs. This study did not examine 
characteristics of the menstrual flow or quality of cervical mucus.5 
Fertility awareness methods can be used to enhance couples chances to achieve 
pregnancy.6 These methods use one or more of several natural biomarkers [i.e., variations in 
cervical mucus characteristics, BBT, cervical checks, and home urinary hormonal kits that 
measure estrone-3-glucuronide (E3G) and luteinizing hormone (LH) levels] to determine the 
fertile window in the cycle or the days when a couple is likely to conceive.7,8 Among these 
biomarkers, the presence of estrogen-stimulated cervical mucus is particularly relevant to 
achieve pregnancy. Previous studies determined that estrogenic mucus enhances the sperm 
motility, storage and transport of normal spermatozoa.9–12 Furthermore, cervical mucus 
discharge methods identify a longer window of fertility than LH kits.13 Identifying the full window 
of fertility may lead to higher rates of conception.14 Therefore, couples trying to conceive after 
discontinuation of OCs may benefit by being able to identify the biomarkers of the women’s 
menstrual cycles, particularly the changes in cervical mucus discharge and the time within their 
cycle they are most likely to conceive. This knowledge could enhance their chances to achieve 
pregnancy. 
The purpose of this study was to determine the characteristics of biomarkers of the 
menstrual cycle [that is, overall menstrual cycle length in addition to estimated length of the 
luteal phase, duration of menses, estimated day of ovulation (follicular phase length), menstrual 
flow score, and mucus score] during the first six menstrual cycles after discontinuation of OCs 
and to compare these with the biomarker characteristics in menstrual cycles of women who had 
not used OCs for at least 1 year previously. 
 
Materials and Methods 
Design 
This retrospective cohort study compared 70 women who had discontinued OCs within 
≤12 weeks (cases) with 70 matched women who had not used OCs for at least 1 year (controls). 
Both groups of women recorded daily observations of vaginal discharge on charts according to 
a standardized protocol, and from these charts, we abstracted information for up to six 
consecutive menstrual cycles for each woman. 
 
Sites 
The 140 women came from three clinical sites in the United States (Atlanta, Georgia; 
Milwaukee, Wisconsin; St Louis, Missouri). The Atlanta site is a private clinic of an obstetrician 
and gynecologist; the Milwaukee site is the Natural Family Planning Institute at Marquette 
University; and the St Louis site is the Department of FertilityCare Services of St. John’s Mercy 
Medical Center. These 140 women were all taught the Creighton Model FertilityCare System 
(CrMS) by either a physician or a nurse who was certified in the CrMS. 
 
Creighton Model Fertility Care System 
The CrMS is a standardized method of natural family planning (NFP) that includes an 
introductory session, structured follow-up visits, and daily observation and charting of 
biomarkers by the woman or couple using the method. Teachers of the CrMS undergo an 
intensive training program that lasts 18 months and an external certification process. 
The CrMS teaches women how to monitor and record biomarkers of the menstrual cycle 
by daily observations of vaginal discharge according to standardized protocols (an example of a 
CrMS menstrual cycle chart is shown in Fig. 1). From the CrMS daily diary or chart, one can 
monitor and interpret characteristics of vaginal bleeding, the vaginal discharge of cervical mucus, 
the estimated day of ovulation, cycle length, and luteal phase length.15 The peak day of 
estrogenic cervical mucus discharge (i.e., the last day of any mucus that is clear, stretchy, or 
lubricative) is a fairly accurate indicator of the day of ovulation with an accuracy of 2–3 days.16,17 
In validation studies with the CrMS specifically, ovulation as assessed by hormonal measures 
occurred between 2 days before and 1 day after peak day in 89.2% of cycles and between 3 
days before and 3 days after peak day in 100% of cycles.18 
All the CrMS charts from the 140 women included in this study are currently housed in 
secure storage in the Marquette University Institute for Natural Family Planning or at Saint 
John’s Mercy Medical Center. The charts represent menstrual cycles from 1985 through 1995. 
The retrospective analysis of these data was approved by the Marquette University Office of 
research compliance, the University of Utah Institutional Review Board for Human Subjects, and 
the St. John’s Mercy Medical Center Institutional Review Board. The database includes no 
identifying information. 
 
Sample 
Women who were new users of the CrMS and between the ages of 18 and 42 were 
sampled. Seventy women who had discontinued use of OCs within ≤12 weeks (cases) were 
randomly matched by age (within 1 year) and parity (parous or nonparous) with 70 women who 
had not used OCs within the past year (controls). The majority of the women were learning the 
CrMS to temporarily avoid pregnancy, but pregnancy intention for use of the CrMS was not a 
selection criterion of this study. Women with a history of infertility and women who were 
breastfeeding were excluded. There was no exclusion based on cycle length. All inclusion, 
exclusion, and matching criteria were determined as of the time the woman started charting with 
the CrMS. Cycles within pairs were matched by sequential cycle number. Because some 
women had one or more missing cycles, the number of matched cycles available for analysis for 
any given cycle number was less than the total number ofmatched pairs ofwomen. In the total 
database, there were 675 cycles; cycles included in the matched pair analysis (n = 230 matched 
pairs, n = 460 cycles) are outlined in Table 1. 
 
Database 
A database was extracted from the CrMS charts of the sample. Each participant 
contributed at least one and no more than six cycles to the database, based on the cycles 
available in her CrMS charts. Demographic information was collected from the standardized 
general intake form completed by the participant before the first follow-up visit. Additionally, 
satisfaction with and confidence in using the CrMS method was assessed at both the first and 
sixth follow-up visits by the CrMS instructor. The first and sixth follow-up visits usually occur 2 
weeks and 6 months after the client starts charting with the CrMS, respectively. Satisfaction was 
assessed on a Likert scale (1–5), with 1 = unsatisfied and 5 = very satisfied. Confidence was 
also assessed on a Likert scale (1–5), with 1 = very unconfident and 5 = very confident, with an 
additional category for overconfident. There were very few responses of overconfident, so 
thesewere collapsed to a response of 5, very confident. 
Potential confounding variables were obtained from the records kept by the CrMS 
practitioner (teacher) at the first follow-up visit (via the standardized follow-up form) and 
included medication use (including antibiotics, antihistamines, vitamins, expectorants, and 
hormones). Medication use was dichotomously coded (consumers, nonconsumers). Further, the 
length of time the woman had taken OCs and time elapsed since discontinuing OCs were also 
obtained from the followup form. The biomarkers of menstrual cycle function, abstracted from 
the participant’s standardized CrMS charts, included cycle length, duration of menses, the 
estimated day of ovulation (EDO) based on the peak day of cervical mucus, the postovulatory 
(luteal) phase (based on the EDO and cycle length), the menstrual flow score, and the cervical 
mucus score. To ensure reliability of the dataset, two CrMS trained health professionals read 
and interpreted each menstrual cycle chart and independently validated the data entries. 
 
Statistical Analysis 
In unmatched analyses, descriptive statistics comparing cases and controls were 
calculated for demographic information, including age, race, marital status, education, 
employment, income, and center of CrMS, along with medication use and menstrual cycle 
function. For cases, length taking OCs and time since discontinuation of OCs were also 
calculated. Exact chi-square and the Student’s t test were used to calculate differences between 
recent OC users and controls on demographic and clinical characteristics and, for the first cycle, 
of biomarkers of menstrual cycle function. 
In matched analyses, linear mixed models using robust standard errors (SE) were used 
to evaluate differences in menstrual cycle function (described in detail below). These random-
intercept models were chosen to account for the correlation between cycles of the matched 
pairs. P values were 2-sided with significance set at 0.05. 
The choice of covariates to adjust for in the mixed models was determined by both 
clinical knowledge and bivariate statistical testing. Medications were initially assessed as 
possible confounders of mucus score, as use could be related to the exposure (recent OC users 
vs. controls) and independently related to the outcome, and center of CrMS instruction was 
assessed for potential confounding of all outcomes. Variables that were significant at the p < 
0.10 level in bivariate analyses (e.g., difference in luteal phase length = intercept + potential 
confounder) were included in the adjusted models. Additionally, any medications that were 
significant at the p < 0.10 level for mucus score were assessed for potential confounding with 
the other outcomes. Statistical tests revealed that only vitamin use among controls was a 
potential confounder for mucus score, and center of CrMS instruction was a potential 
confounder for menstrual flow score. 
Because neither exposure nor covariates were time varying, nonweighted models were 
deemed appropriate. Due to the limited number of independent variables (none of which were 
continuous), checking for linearity, interactions, and multicollinearity was not necessary. Models 
for each of the six outcomes were assessed via residual plots, histograms of the residuals to 
check for normality and examination of potential outliers. SAS (version 9.2, SAS Institute Inc, 
Cary, NC) was used for all data analyses. 
 
Definitions 
Cycle Length 
The number of days from the first day of menses (as recorded on the CrMS chart by a 
woman) to the last day of the cycle before the beginning of the next menses. 
 
Estimated Day of Ovulation (EDO) 
For this study, the number of days counted from the first day of menstrual flow through 
the peak day of cervical mucus, the latter of which was validated retrospectively by professional 
CrMS teachers. 
 
Length of Luteal Phase 
The number of days counted from the first day after the EDO through the last day of the 
menstrual cycle. 
 
Length of Menses 
The number of days of continuous usual bleeding at the beginning of a menstrual cycle 
as charted by the participant. 
 
  
Mucus Score 
This is an index developed by Hilgers19 to estimate the quality of the cervical mucus of 
each day within the fertile window (i.e., EDO and the 5 days before it). The system takes into 
consideration the color, consistency, sensation, and change of the cervical mucus, giving a 
numerical rate of 0–4 for each of the parameters on each day. The score on each day ranges 
from 0 to 16. The scores for the 6 days of the fertile window are averaged. A regular cervical 
mucus score ranges from 9.1 to 16, with the maximum score being 16. 
 
Menstrual Flow Score 
This is an index developed by Hilgers18 as a qualitative estimate of the intensity of 
menstrual flow. The index is based on points assigned for a woman recording each day of 
heavy bleeding (12 points), moderate bleeding (8 points), light bleeding (4 points), very light 
bleeding (2 points), brown bleeding (1 point) and takes the mean of the points assigned each 
day for the first 6 days of the menstrual cycle. 
 
Results 
Demographics 
There were no statistically significant differences in the mean age, race, education, 
employment status, income, or center of CrMS study between the recent OC users and controls 
(Table 2). Recent OC users were more likely to be married than controls (p < 0.0001) and have 
incomes >$40,000 (p = 0.01). 
 
Satisfaction and Confidence in Using the CrMS 
There were no significant differences in either satisfaction with or confidence in using the 
CrMS between cases and controls (both for the women and their partners) after both the first 
and sixth follow-up visits (Table 3). 
 
Menstrual Cycle Characteristics 
Descriptives of menstrual cycle characteristics in unmatched, unadjusted analyses for 
the first cycle after beginning CrMS instruction are shown in Table 2. Controls had longer 
duration of menses (6.2 vs. 5.5 days, p = 0.004) along with higher scores for intensity of 
menstrual flow (6.2 vs. 4.9, p = 0.0001) and mucus quality (9.0 vs. 7.3, p = 0.01). 
As shown in Table 4, matched pair analyses assessed the difference in menstrual cycle 
biomarkers for the first two cycles combined and the first six cycles combined after beginning 
CrMS instruction. For the first two cycles, significant differences were found for recent OC users 
for menses duration (shorter) and estimated day of ovulation (later). Similar trends were seen 
when looking at the six combined cycles after beginning CrMS, with significant differences found 
for case length of the cycle (longer) and EDO (later). Both mucus and menses cycle score 
differences were significantly lower for recent OC users compared to controls for the first two 
and six consecutive cycles (p < 0.005). In cycle-specific analyses, the difference for the mucus 
score persisted but was not statistically significant for individual menstrual cycles after the 
second cycle (Fig. 2). The difference for the menses score was attenuated and no longer 
statistically significant after the fourth cycle (Fig. 3). The difference in the estimated day of 
ovulation seemed to persist but was significant only for the individual second cycle (Fig. 4). 
Neither restricting all six outcome analyses to women who had cycle lengths <60 days nor 
deleting observations with residuals in the first or last percentiles significantly altered the results. 
For the recent OC users, on average, there was a 23.9 day gap (range 0–77 days) 
between discontinuing OCs and the beginning of CrMS charting. To investigate whether women 
who had a longer gap influenced the results, we repeated the analyses excluding all matched 
pairs with women who had stopped OCs for ≥30 days before starting to chart with the CrMS (n = 
156). The results were all substantively similar to those we have reported, except that 
confidence intervals (CIs) were wider because of the smaller sample size (data not shown).  
 
Discussion 
After discontinuation of OCs, women on average will experience longer cycles as well as 
more variability in cycle length and EDOthanwomen who have not recently used OCs. A similar 
finding was observed by Rice-Wray et al.3 and by Larsson-Cohn4 in their studies of menstrual 
cycle after discontinuation of OCs. The average menstrual cycle length for non-OC users has 
been reported to be 28.9 ± 3.4 days. This value is in agreement with the average menstrual 
cycle length for our control group 29.8 ± 6.9 days; however, the recent users of OCs had an 
average menstrual cycle length of 31.5 ± 11.1 days (our study) and 36 days in other studies, 
which are well above the value reported for non-OC users.3,4 Gnoth et al.5 also reported an 
increase in the average menstrual cycle length. The average menstrual cycle lengths in the first 
three cycles of their study were 33.3 days after OC discontinuation compared with 29.6 days for 
non-OC users, which is in agreement with our study. This prolongation of the menstrual cycle 
post-OCs is thought to be due to the time needed for the hypothalamuspituitary- ovarian axis to 
normalize after its suppression secondary to the intake of OCs and is reflected in longer 
follicular phases. On the other hand, Duijkers et al.20 have reported a normal duration of the first 
cycle after discontinuation of OCs as compared with womenwho were not taking OCs, that is, 
30 days and 29 days, respectively. 
In our study, the number of days to EDO (follicular phase) for the first cycle post-OC 
discontinuation was 20.4 ± 11.4 and 18.5 ± 6.7 days for the case and control groups, 
respectively. Birtch et al.21 reported the length of the preovulatory phase of the first menstrual 
cycle after OC discontinuation as being 20.5 ± 1.0 days, which is in good agreement with our 
study group. In addition, a study from Jukic et al.22 showed that women with recent use of OCs 
had a longer follicular phase by a mean of 2.3 days compared to those women who did not use 
OCs. This finding is in close agreement with our study, where an increase of approximately 2 
days was observed among the post-OC group compared to the control group. The duration of 
the follicular and luteal phases for the control group in cycle 1 (18.5 and 11.5 days, respectively) 
is slightly longer and shorter, respectively, than the durations reported in other recent studies 
with roughly similar age distributions of women. A European study of 782 women and 6724 
cycles reported a mean follicular phase length of 16.3 days and a mean luteal phase length of 
12.7 days,23 whereas in the study by Gnoth et al.,5 the first cycle in the control group (n = 254) 
had a mean follicular phase length of 17.0 days and a mean luteal phase length of 12.1 days. 
The presence of high-quality cervical mucus during a woman’s menstrual cycle is a very 
important factor for a couple attempting to achieve pregnancy because cervical mucus 
enhances sperm survival and transport.24 It is of interest that the mean cervical mucus scores 
for both the recent OC users (9.0) and control women (7.3) fell below the range of a regular 
mucus cycle score (9.1–16).19 The normal variability of the cervical mucus score with other 
factors, such as age and parity, has not been systematically assessed. The probability of 
pregnancy with intercourse on days with no cervical secretion is near zero.25 It has also been 
shown that a lower quality of mucus discharge as assessed with different measures, including 
the CrMS mucus score, correlates with a lower probability of conception.14,24,26 Fehring16 
showed that 97.8% of the peak day mucus fell within ±4 days of the LH surge within a menstrual 
cycle. In addition, Stanford et al.13 provided evidence that the maximum probability of 
conception differs significantly by mucus quality, as assessed by the CrMS mucus score; a 
mucus score change of 2 corresponds to an absolute change in the per cycle probability of 
conception of about 5%. The presence of peak day mucus correlates well with the rising of 
estrogen levels in the blood.18 Our study showed that not only for the first but also for the 
combined first six menstrual cycles after discontinuation of OCs the quality of the cervical 
mucus was diminished compared with that of the control group. We know of no other study that 
has reported on the cervical mucus quality after OC discontinuation. 
We also found that recent OC users had decreased menstrual flow, as assessed by 
duration of menses and the menstrual flow score, which measures menstrual intensity based on 
the woman’s subjective assessment. It is well known that OCs decrease the length and flow of 
menses (OC withdrawal bleeding) by ≥60% during their use.27 This decrease in menses flow 
and length is most likely caused by a substantial thinning of the endometrium thickness in 
women taking OCs.28 Therefore, the initial decrease in the length of the menses and menstrual 
flow score in women discontinuing OCs is not surprising. Our results suggest that it takes the 
endometrium at least six cycles after OC use to return to a normal intensity of flow. A thinner 
endometrium has been shown to be correlated with a lower likelihood of implantation in the 
setting of assisted reproduction.29 
 
Limitations 
The OC effects on menstrual cycle biomarkers might endure for up to 9 months, as 
reported by Gnoth et al.5 but by design, our study assessed only the first six cycles and had 
limited power because of the decreasing number of contributing cycles at each cycle number. 
The lack of statistical power for individual cycles limits our ability to define the exact duration of 
the continued effects of prior OC use. Whereas some parameters clearly attenuated with time 
(i.e., the menses score) (Fig. 3), others seemed to continue to have differences of similar 
magnitude across cycles (i.e., the mucus score and the EDO) (Figs. 2 and 4). In these latter 
cases, the combined analysis of cycles 1–6 is appropriate to increase the power of the analysis 
(Table 4) by combining multiple cycles. 
More precise measures of when menstrual cycle function returns to normal are 
necessary, but our results corroborate other studies that show a delay of return to full fecundity. 
This initial reduction in fecundity could be a result of mistimed intercourse because of delayed 
fertile phases, decreased quality of cervical mucus adversely impacting sperm survival, 
decreased thickness of the endometrium lowering the probability of implantation, or a 
combination of these factors. Our study was a retrospective study but was based on clinical 
records that were completed prospectively at the time the women were beginning use of the 
CrMS. Our careful matching process seems to have compensated for possible confounding 
variables of age and parity. A prospectively conducted study would likely have a very similar 
design but could include additional helpful biomarkers, such as hormonal measures. Conducting 
a prospective randomized clinical trial for this question would be ethically problematic because it 
would require randomizing women to take OCs and then stop taking them. 
We cannot exclude the possibility that some of the women who are recent OC users 
were initially placed in the OC to regulate their otherwise irregular menstrual cycles. After the 
discontinuation of OCs, such women may return to a pattern of irregular menstrual cycles, which 
could have contributed to the large variability in the standard deviation in the menstrual cycle 
length. However, there was no exclusion by cycle length in our study, such that women with 
longer and irregular menstrual cycles were included in the control group. Limiting the analysis to 
women who had cycles <60 days (in both the OC and control groups) did not substantially alter 
our results. Another limitation is that cervical mucus is an imperfect means of identifying the 
exact day of ovulation. However, any variability introduced by this indicator for ovulation would 
not be expected to differ systematically between women who are recent OC users and women 
who are not. In our sample, recent OC users were more likely to be married and have higher 
income. It is possible that they would, therefore, be more likely interested in achieving 
pregnancy, but it is difficult to predict what relationship this would have with cycle parameters. 
Marriage might be associated with more or less stress, and higher income might be associated 
with less overweight (more regular cycles) or more consistent vigorous exercise (possibly more 
irregular cycles). Although race and ethnicity are not thought to directly affect menstrual cycle 
function, future studies involving women from various racial=ethnic backgrounds are 
recommended. Some of the women in the control group may have used OCs >1 year before the 
study. Although the effects of past use of OCs are not thought to last for more than 12 months, 
future studies should clarify and control for a woman’s complete history of OC use. Finally, the 
types of OCs in use during the time of this study were generally of somewhat higher dose than 
the types of OCs in use today. It will be important to replicate this study with current 
formulations of OCs. 
In spite of these limitations, our results offer potential explanatory mechanisms for the 
Wiegratz et al. study,30 which showed a 15% decrease in conception rate in the first 3 months of 
the discontinuation of OCs. In addition, Birtch et al.31 found clinically low levels of progesterone 
in 40% of the cycles after discontinuation of OCs. They hypothesize that low levels of 
progesterone could result from luteal phase dysfunction, which would further explain the delay 
in fertility on post-OC women. 
For those couples who wish to avoid pregnancy with the CrMS after discontinuing OCs, 
the similar confidence and satisfaction scores found in this study are reassuring. Previous work 
has demonstrated that the effectiveness of the CrMS to avoid pregnancy is equally good for 
those discontinuing OCs as for those with no recent use of hormonal contraception.25 For those 
couples who wish to conceive after discontinuing OCs, practitioners can use this information to 
ease couples’ anxiety about delays in achieving pregnancy after discontinuation of OCs. In 
addition, they can provide couples with useful information on how to increase their chances to 
achieve pregnancy, such as learning how to determine their fertile window through the use of 
natural biomarkers (especially biomarkers that prospectively identify the fertile window: cervical 
mucus or levels of urinary estrogen) and to focus intercourse during the estimated fertile 
window.7,14 Gnoth et al.32 found that by using timed intercourse during the estimated fertile 
phase, 88% of fertile couples (including couples discontinuing OCs) can achieve pregnancy 
within 6 months. 
 
Conclusions 
Statistically significant differences in several biomarkers of the women’s menstrual cycle 
were observed after discontinuation of OCs. These changes may help explain why there is a 
decrease in the chances for a couple to conceive within the first few months after 
discontinuation of OCs. There is a trend toward normalization of some of these parameters over 
the first six menstrual cycles of discontinuation of OCs. Confidence and satisfaction in use of the 
CrMS did not differ between women discontinuing OCs and those not using OCs. 
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Appendix 
Fig. 1: Creighton Model FertilityCare Sysetm (CrMS) Example Chart 
(Courtesy of T. W. Hilgers, Pope Paul VI Institute, Omaha, NE.) 
 
 
Fig. 2 
 
 
 
Mean difference in mucus score between recent oral contraceptive (OC) users and controls, 
adjusted forv itamin use by controls (positive indicates that recent OC users have the larger 
value). Number of matched pairs in each cycle can be found in Table 1. 
 
Fig. 3 
 
 
 
Mean difference in menses score between recent OC users and controls, adjusted for CrMS 
center of instruction (positive indicates that recent OC users have the larger value). Number of 
matched pairs in each cycle can be found in Table 1. 
 
Fig. 4 
 
 
 
Mean difference in estimated day of ovulation between recent OC users and controls (positive 
indicates that recent OC users have the latter day). Number of matched pairs in each cycle can 
be found in Table 1. 
 
Table 1: Matched Pairs of Cycle by Cycle Number: Recent Oral 
Contraceptive Users Matched with Controls 
 
 
 
Table 2: Characteristics of Study Population According to Group 
 
 
aDue to four matched pairs with a cycle 1, total number of women analyzed was 132. 
CrMS, Creighton Model Fertility Care System; OC, oral contraceptives; SD, standard deviation. 
 
Table 3: Satisfaction and Confidence with CrMS According to Group (Scale 
of 1-5) 
 
 
 
Table 4: Adjusted Mean Difference in Cycle Parameters between Recent 
Oral Contraceptive Users and Controls 
 
 
 
Positive means recent OC users have the larger value or later day. 
*p < 0.05; **p < 0.005. 
aAdjusted for CrMS center of instruction. 
bAdjusted for vitamin use by controls. 
CI, confidence interval. 
